Skip to content

Comparison of efficacy and safety of amphotericin B preparations in the treatment of invasive fungal infections: a multicenter retrospective cohort study.

Comparison of efficacy and safety of amphotericin B preparations in the treatment of invasive fungal infections: a multicenter retrospective cohort study.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127060
Enrollment
Unknown
Registered
2026-06-23
Start date
2026-06-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive fungal infection

Interventions

1. Amphotericin B liposomes 2. Amphotericin B cholesterol sulfate lipid complex or amphotericin B deoxycholate:None

Sponsors

The first affiliated hostipal of nanchang university
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Cases where different preparations of amphotericin B (AmB, ABCD, L-AmB) were used continuously for more than three days; 2. Cases of invasive fungal infections with clinical diagnoses (such as Cryptococcus, Aspergillus, Mucor, Malnefi, etc.); 3. For special groups (such as those with malignant blood diseases, hematopoietic stem cell transplantation, or solid organ transplantation), corresponding host factors (such as neutrophil deficiency for =10 days, having received allogeneic hematopoietic stem cell transplantation, long-term history of glucocorticoid or immunosuppressant use, etc.) must be present.

Exclusion criteria

Exclusion criteria: 1. Incomplete data or missing key information (such as lack of laboratory tests, medication records, follow-up outcomes, etc.); 2. Amphotericin B was used for less than 3 days or was interrupted during the treatment period; 3. Death or irreversible renal function impairment caused by other reasons (such as severe bacterial infection, surgical complications, etc.) that cannot be attributed to amphotericin B; 4. Patients who do not meet the requirements of host factors (such as no neutrophil deficiency, no immunosuppressive therapy, etc.) do not fall within the definition of high-risk groups for invasive fungal infections.

Design outcomes

Primary

MeasureTime frame
Site of infection;Amphotericin B dosage and administration regimen;Duration of treatment;Concomitant antimicrobial agents used;Clinical response (cure, improvement, no change, failure);Microbiological outcome (eradication, presumed eradication, replacement, reinfection, persistence);

Countries

China

Contacts

Public ContactLiu Jian

The first affiliated hostipal of nanchang university

812347602@qq.com+86 791 88692482

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026